Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 191.7% on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.50 ($0.04). 104,299,430 shares traded hands during trading, an increase of 470% from the average session volume of 18,292,627 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Price Performance
The firm has a 50 day moving average of GBX 1.36 and a two-hundred day moving average of GBX 1.63. The stock has a market cap of £14.58 million, a PE ratio of -350.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Calculate Return on Investment (ROI)
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is the Nikkei 225 index?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
